

In the Claims

Applicant has submitted a new complete set of claims with insertions indicated by underlining and deletions indicated by ~~striketroughs~~.

1-103. (canceled)

104. (currently amended) A method for treating a vertebrate subject having a tumor, comprising:

administering to a ~~vertebrate~~ the subject ~~having a tumor~~ a tumor-specific antigen and an effective amount of an oligonucleotide 10-50 nucleotides long comprising a sequence chosen from GGGGG, GAGGG, GGGAG, GTGGG, and GGGTG, wherein the oligonucleotide does not comprise a CG dinucleotide, ~~in order~~ to treat the subject.

105. (original) The method of claim 104, wherein the oligonucleotide is DNA.

106. (original) The method of claim 104, wherein the oligonucleotide is RNA.

107. (original) The method of claim 104, wherein at least one nucleotide of the oligonucleotide is replaced by a corresponding nucleotide analog or derivative.

108. (currently amended) The method of claim 104, wherein at least one nucleotide of the sequence chosen from GGGGG, GAGGG, GGGAG, GTGGG, and GGGTG is replaced by a corresponding nucleotide analog or derivative.

109. (original) The method of claim 104, wherein at least two nucleotides of the oligonucleotide are linked by a nuclease-resistant bond.

110. (original) The method of claim 109, wherein the nuclease-resistant bond is selected from the group consisting of phosphorothioate, methylphosphonate, and peptide bonds.

111. (canceled)

112. (previously presented) The method of claim 104, wherein the oligonucleotide is 13-30 nucleotides long.

113. (original) The method of claim 104, wherein the oligonucleotide is 17-21 nucleotides long.

114. (original) The method of claim 104, wherein the sequence represents the 3' terminus of the oligonucleotide.

115-171. (canceled)